Emergency Med Medical News about acute coronary syndromes; eptifibatide

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Eptifibatide: The evidence for its role in the management of acute coronary syndromes
Core Evidence, 08/05/09

Shah I et al. – Several large, randomized controlled trials show that eptifibatide as adjunctive therapy to standard care in patients with non–ST segment elevation acute coronary syndrome is associated with a significant reduction in the incidence of death or myocardial infarction. Data are limited regarding the use of eptifibatide in patients with ST segment elevation myocardial infarction. Cost–effectiveness analysis indicates that eptifibatide is associated with a favorable cost–effectiveness ratio relative to standard care. According to US cost–effectiveness analysis about 70% of the acquisition costs of eptifibatide are offset by the reduced medical resource consumption during the first year. Eptifibatide was well tolerated in most of the trials. Bleeding is the most commonly reported adverse event, with most major bleeding episodes occurring at the vascular access site. Major intracranial bleeds, stroke, or profound thrombocytopenia rarely occurred during eptifibatide treatment.

<< Previous
Traumatic subdural hydroma: Clinical characteristics and...

Next >>
Traumatic urethral injuries: Does the digital rectal examination...

Acute Coronary Syndromes: Diagnosis and Management, Part II
Mayo Clinic Proceedings, 11/03/09 Relevance Score: 83%

Activated factor XII type A and B-type natriuretic peptide are complementary and incremental predictors of mortality in patients following admission with acute coronary syndrome
Blood Coagulation & Fibrinolysis, 11/03/09 Relevance Score: 83%

Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study
Atherosclerosis, 10/13/09 Relevance Score: 83%

Effects of Nordic Walking training on exercise capacity and fitness in men participating in early, short-term inpatient cardiac rehabilitation after an acute coronary syndrome — a controlled trial
Clinical Rehabilitation, 11/12/09 Relevance Score: 82%

Management of acute coronary syndrome in a case of Behcets disease
Blood Coagulation & Fibrinolysis, 11/03/09 Relevance Score: 82%